Furthermore, TLR-9 agonists and IDO pharmacological inhibitors have been shown to convert Tregs into helpers of CD8 T cell responses, suggesting that Treg depletion may not be optimal in certain tumor immunotherapy settings [47]. The gene discussed is CD8A; the disease is neoplasm.